Skip to content

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05902221
Acronym
RIFACute
Enrollment
235
Registered
2023-06-13
Start date
2024-05-02
Completion date
2028-05-01
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections Joint Prosthetic

Brief summary

Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.

Interventions

DRUGamoxicillin or moxifloxacin

Antibiotic treatment back bone during 12 weeks

DRUGamoxicillin or moxifloxacin + rifampicin

Antibiotic treatment back bone during 12 weeks + rifampicin

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicenter, randomized two-arm (parallel) comparative open-label cohort clinical trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age: \> or =18 years old; * Monomicrobial, rifampicin susceptible Cutibacterium acnes late total knee arthroplasty (TKA) or hip arthroplasty (total, THA or hemiarthroplasty, HH) or shoulder arthroplasty (total, TSA or hemiarthroplasty, SH) infection treated surgically with single-stage or two-stage revision; * Isolation of C. acnes on two distinct per-operative samples collected during the single-stage or the two-stage revision * Based on the antimicrobial susceptibility test of the C. acnes and the medical history of the patient, the PJI can be treated with amoxicillin or moxifloxacin; * Women considered of childbearing potential (WOCBP) requires use of a highly effective contraceptive measure as intrauterine device (IUD), intrauterine hormone-releasing system (IUS), documented bilateral tubal occlusion, documented vasectomised partner, sexual abstinence. Contraception should be maintained during treatment and until the end of relevant systemic exposure.

Exclusion criteria

* Contraindication to Rifampicin (included ongoing treatment contraindicated with rifampicin) * Contraindication to Amoxicillin AND moxifloxacin (included ongoing treatment contraindicated with these medicines) * Empirical antibiotic treatment not administered during the 24 hours following revision surgery; * Inactive empirical antibiotic treatment following surgery according to the AST of the bacteria; * disease-modifying treatment incompatible with the inducer effect of rifampicin * Liver cirrhosis; * Pregnancy: a pregnancy blood test will be performed on all women of childbearing age. The results will be sent to the patient by the doctor of their choice; * Porphyria; * Renal insufficiency with GFR \< 30ml/min/1.73 m2 (CKD-EPI);

Design outcomes

Primary

MeasureTime frameDescription
Rate of C. acnes prosthetic joint infections management failure24 months after the end of antibiotic treatmentDefined by Relapse, New infection, early failure
Rate of adverse event linked to rifampicinduring rifampicin treatmentadverse events will be described by frequency and grade, throughout the treatment (classified according to the CTCAE 5.0.)

Secondary

MeasureTime frameDescription
Rate of C. acnes prosthetic joint infections probable failure24 months after the end of antibiotic treatmentprosthetic joint infections probable failure suspected in case of specific clinical signs (fistula) and/or inflammatory synovial fluid without microbiological positive results and/or histopathological results after revision without microbiological positive results
Rate of C. acnes prosthetic joint infections management failure24 months after the end of antibiotic treatmentDefined by Relapse, New infection, early failure

Countries

France

Contacts

CONTACTJohan COURJON, MD
courjon.j@chu-nice.fr+33(0)492034562

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026